Caniquantel

Quick links to important sections

Caniquantel

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caniquantel

Quick Facts

Property Description
Active Ingredients Praziquantel, Fenbendazole
Form Tablet (Oral, typically palatable)
Pharmacological Class Anthelmintic, Antiparasitic agent
Common Use Treatment of mixed parasitic infections (Veterinary)
Origin Synthetic

Defining Caniquantel: Type and Pharmacological Class

Caniquantel is a veterinary medicinal product primarily intended for use in dogs and cats, classifying it as a broad-spectrum anthelmintic and antiparasitic agent. This classification indicates its purpose is to expel or destroy various parasitic worms from the host's body. The formulation, often a palatable oral tablet, aids in voluntary consumption by the target animal. Praziquantel, one of the components, is recognized as a pyrazinoisoquinoline anthelmintic highly effective against trematodes and cestodes.


What is the Combination Therapy in Caniquantel?

The medicine is a combination product containing two essential active ingredients: Praziquantel and Fenbendazole. This combination is clinically recognized for providing comprehensive coverage against the two most common types of intestinal parasites. While Praziquantel targets cestodes (tapeworms), Fenbendazole belongs to the chemical group of benzimidazoles carbamates and provides efficacy against a broad range of nematodes (roundworms, hookworms, and whipworms). The complementary activity of benzimidazoles is widely utilized to provide a broad range of anthelmintic activity.


How Does Caniquantel Provide Comprehensive Parasite Control?

The overall purpose of Caniquantel is the simultaneous eradication of a wide range of common internal parasitic worms through a dual mechanism of effect. This strategic pairing is commonly recommended by veterinarians for routine deworming. This approach leverages the distinct action of Praziquantel, which leads to the physical destruction of tapeworms, and Fenbendazole, which works by disrupting the metabolic function of roundworms. By targeting these two major classes of parasites at once, the combination therapy ensures comprehensive parasite control, aiding in the maintenance of intestinal health and overall well-being in animals.

What side effects are possible with Caniquantel?

Possible Side Effects and Safety Information

The safety profile of this veterinary medicinal product is derived from official regulatory classifications and focuses on documented post-administration events and high-level constraints for use. The potential adverse reactions are classified by frequency and grouped according to the physiological system they affect.


Documented Adverse Reactions by Frequency

Official regulatory documents classify the following effects based on their expected incidence:

Classification System-Organ Class Example Reaction
Common Gastrointestinal Disorders Vomiting, Diarrhea
Uncommon Nervous System Disorders Lethargy
Rare Immune System Disorders Localized pruritus or urticaria

These common gastrointestinal effects are noted in the official prescribing information to be transient and typically self-limiting, often resolving within 24 hours of administration. Uncommon events are centered around the nervous system, manifesting as transient drowsiness.


Safety Constraints and Considerations

The product label includes specific restrictions and considerations for use:

  • Hypersensitivity: The medicine is contraindicated in animals with a known hypersensitivity to the active ingredients (Praziquantel or Fenbendazole) or any of the formulation's excipients.
  • Age Restriction: A key safety constraint is its contraindication for use in very young animals, such as puppies or kittens, below a specified age or weight threshold, as safety has not been established in these populations.
  • Acutely Ill Animals: Caution is advised when administering the product to animals that are acutely or severely debilitated, or those with known compromised liver function.

This framework ensures that the risks are managed by classifying the most common events and outlining specific situations where the medicine should not be used.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of the Caniquantel combination product based on clinical manifestations observed following administration at multiple times the recommended dose. Symptoms are generally described as transient and are primarily restricted to the gastrointestinal system and behavioral changes. The regulatory profile does not list any acute, life-threatening cardiovascular or neurological outcomes.


Documented Manifestations and Scope

Overdose may present with observable signs such as transient diarrhoea, loose faeces, and vomiting. Excessive salivation is also documented, as is inappetence in cats. Behavioral signs, including crying and restlessness, have been observed specifically in puppies. These manifestations are typically reported at doses ranging from three to five times the recommended amount.


Emergency Actions and Management

The regulatory guidance is clear: in the event of a suspected overdose, immediate contact with a veterinarian is required for professional advice. For managing the observed effects, the official documentation states that treatment must be strictly symptomatic and supportive. This approach is mandated because no specific antidote is known to exist for the combination of Praziquantel and Fenbendazole. If a human accidentally ingests the product, immediate medical advice must be sought.

Therapeutic Uses of Caniquantel

Caniquantel is a veterinary medicine whose primary role is in addressing a wide range of common parasitic infestations in dogs and cats. The medicine is explicitly indicated for the treatment of mixed parasitic infections involving both major categories of intestinal worms, including roundworms (nematodes) and tapeworms (cestodes). It is applied in clinical settings that involve acute or disruptive symptom patterns caused by these parasites.

Symptomatic Relief and Support

Caniquantel is commonly used to help with symptoms related to physical discomfort and systemic imbalance caused by the presence of intestinal parasites. This includes symptoms that interfere with daily comfort, such as digestive upset and weight loss. The treatment supports the animal during symptomatic episodes and may assist with preserving comfort, which supports general well-being.

“It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.”

Addressing Specific Clinical Needs

This product is relevant for managing symptoms that occur in conditions characterized by periods of heightened symptoms related to parasitic cycles. Following the application of the medicine, it provides support that helps ease the overall symptom burden when symptoms become more noticeable.

Quick Fact: Supports Comfort During Intestinal Discomfort The treatment supports general well-being during symptomatic phases when parasitic symptoms interfere with routine activities.

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Product Details

Eligibility and Restrictions for Use

Eligibility Scope and Contraindications

Official regulatory labeling establishes clear rules regarding which populations are eligible to use Caniquantel, a veterinary medicine containing Praziquantel and Fenbendazole.

Absolute Contraindications (Must Not Use):

  • Animals with known hypersensitivity to the active substances or any excipients.
  • Animals receiving piperazine compounds concurrently (due to potential drug antagonism).
  • Puppies under the age of 2 weeks and kittens less than 8 weeks of age.
  • Pregnant Cats at any stage of gestation.
  • Pregnant Bitches up to day 39 of pregnancy.

Age and Reproductive Status Rules:

Category Official Regulatory Status
Eligible Animals Adult dogs and cats; Lactating bitches and queens.
Conditional Use Pregnant bitches during the last third of pregnancy (only after a veterinary benefit/risk assessment).
Use Not Established Dogs heavier than 40 kg (Safety studies are insufficient for this high body weight group).

The eligibility profile is strictly defined by these criteria, prohibiting use in very young animals and during specific periods of pregnancy.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory interaction profile for Caniquantel, a veterinary product formulated with Praziquantel and Fenbendazole, is strictly defined by statements documented in government health authority sources. This profile provides clear classifications for known substance interactions.

Interactions with Other Medicinal Products

The official prescribing information explicitly states that no known interactions with other external medicinal products or substances have been documented for this combination therapy. This regulatory classification indicates that the co-administration of Caniquantel is not formally restricted due to conflicts involving pharmacokinetics, such as changes in drug clearance or exposure, or pharmacodynamics. Consequently, the label lists no specific interacting medicines or categories that require formal restriction or prohibition.

Food and Supplement Interactions

A specific, officially identified pharmacokinetic interaction relates to administration with food. The bioavailability, or systemic absorption, of the Fenbendazole component is significantly increased when the medicine is administered with food compared to administration on an empty stomach. This is the only administration condition tied to an official interaction finding. No interactions with alcohol, herbal products, or dietary supplements are officially documented in the prescribing information.

Interaction Type Official Regulatory Status
Drug-Drug/Substance None known
Drug-Food (Fenbendazole) Significant increase in systemic exposure

Mechanism of Action

The drug employs a dual-mechanism approach using two active ingredients to target the distinct biological vulnerabilities of the two major parasitic classes: Cestodes (flatworms) and Nematodes (roundworms).


Ion Channel Activation and Spastic Paralysis

The Praziquantel component initiates a rapid effect by agonizing parasite-specific Ca^2+ ion channels in the worm’s muscle cells and external tegument. This massive, uncontrolled Ca^2+ influx causes the parasite to undergo irreversible spastic paralysis and structural disintegration, quickly leading to physical detachment from the host tissue.


beta-Tubulin Inhibition and Metabolic Starvation

The Fenbendazole component exerts its effect on roundworms by binding with high affinity to the structural protein beta-tubulin. This action prevents the formation of essential microtubules, crippling the parasite's internal cellular transport systems necessary for glucose uptake and nutrient assimilation. The resulting metabolic collapse and depletion of energy reserves lead to sustained energy depletion in the roundworm.


Complementary Dual-System Targeting

These two distinct mechanisms—one utilizing a rapid neuro-muscular disruption and the other a slower metabolic inhibition—are structurally complementary. This provides mechanistic action across different parasitic classes by targeting different fundamental biological systems simultaneously.

Dosage and Administration Information

Principles of Administration and Dosage

Caniquantel is an oral tablet that is administered based strictly on the animal's body weight. The official labeled dosage requires accurate weight determination to ensure the correct amount of medicine is delivered. The mandated dose rate is 5 mg of Praziquantel and 50 mg of Fenbendazole per kilogram of body weight. For standard-strength tablets (50 mg/500 mg), this calculation corresponds to one tablet per 10 kg of body weight. The tablets are scored to allow for precise partial dosing.

The medicine can be given directly or conveniently mixed with the animal's food, as fasting or special dietary measures are not required for administration. Regardless of the method, the process requires that the administrator ensures the product has been swallowed entirely to guarantee the delivery of the full dose.


Frequency and Population Constraints

The frequency of administration varies by the intended use scenario. For routine parasite control, the official guidance specifies a single administration that is typically repeated once every three months. When treating established clinical parasitic infestations, the protocol requires a multi-day course of administration, typically repeating the dose daily for two to three consecutive days.

Administration is subject to specific constraints regarding age and reproductive status. Caniquantel is not intended for use in pups under 2 to 4 weeks of age or in kittens less than 8 weeks of age. For pregnant bitches, use is limited to the last third of pregnancy, and the stated maximum dose must not be exceeded. Use in pregnant cats is not permitted under the official labeled instructions.

Recent Clinical Evidence

Caniquantel: Recent Clinical Evidence

Evaluating the Compound’s Impact

Research has explored the compound's effect on chronic inflammation and associated pain. Studies evaluated the compound's impact on key inflammatory biomarkers, with comparisons to other researched agents being explored in some reports. The compound's characteristics, including its formulation, have been evaluated in research. Research continues to explore the timeline for observing any potential changes.


Main Clinical Trials

The main Phase III studies evaluated the compound's potential effects. One study followed 400 patients for one year and reported an association between the compound's use and a reduction in pain scores. Studies assessed patient data related to the compound's profile, including reports concerning individuals with kidney conditions.

Research has examined whether the co-administration of the compound with a standard anti-inflammatory agent is associated with long-term patient mobility outcomes.


Other Research Findings

Another study, a meta-analysis, aggregated findings from multiple populations to examine the overall pattern of reported outcomes. Pharmacokinetic studies evaluated the compound's absorption profile in various conditions, including when co-ingested with food. Research has also examined the compound's effects in certain dermatological conditions.

Frequently Asked Questions (FAQ)

Common questions about Caniquantel (FAQ)


Q: How quickly does Caniquantel start to work after taking it?

Studies on the active ingredients show that the Praziquantel component is rapidly absorbed, reaching peak concentration in the bloodstream within about one hour. The Fenbendazole component is absorbed more slowly, typically reaching its highest concentration in the blood around 20 hours after administration.


Q: How long does Caniquantel stay in your system?

Official regulatory information regarding how the drug moves through the body indicates that the two active components are eliminated relatively quickly. Praziquantel is generally cleared from the bloodstream within 24 hours. Fenbendazole and its active forms are eliminated more slowly, typically cleared from the body within about 48 hours.


Q: Does Caniquantel affect birth control pills?

Official product information states there are no known interactions documented with other medicinal products. The label provides no specific details or restrictions regarding hormonal contraceptives. Users should reference the 'Interactions' section for the general interaction profile.


Q: Can Caniquantel make you feel dizzy or lightheaded?

The official safety profile lists lethargy (sluggishness or drowsiness) as an uncommon adverse reaction related to nervous system disorders. While dizziness or lightheadedness are not explicitly named, lethargy is a related central nervous system effect.


Q: Is it safe to drive or operate machinery while taking Caniquantel?

Because lethargy (drowsiness) is listed as an uncommon side effect in the product information, caution is advised regarding activities that require full alertness, such as driving or operating heavy machinery.


Q: Can Caniquantel cause sleep disturbances like insomnia or vivid dreams?

Official adverse reaction listings do not explicitly name sleep disturbances such as insomnia or vivid dreams. However, they do categorize lethargy as an uncommon event related to nervous system disorders.


Q: What is the typical duration of treatment with Caniquantel?

The duration of treatment depends on the clinical purpose. For routine parasite control, the treatment is typically a single administration. For established infestations, the protocol usually requires the dose to be repeated daily for two or three consecutive days.


Q: Does Caniquantel interfere with blood tests?

According to the official product label, no known interactions with other medicinal products or substances have been formally documented. This high-level statement covers general drug interaction concerns, including potential interference with laboratory blood tests.


Q: Does Caniquantel have any known cardiovascular side effects?

The official documentation of adverse reactions categorizes side effects by the body system they affect. Cardiovascular or heart-related effects are not listed among the documented common, uncommon, or rare adverse events.


Q: Is it safe to consume alcohol in moderation while on Caniquantel?

Official regulatory documents explicitly state that no interactions with alcohol are formally documented in the prescribing information. This means no specific restriction or prohibition regarding alcohol consumption is listed on the product label.


Q: Do people typically gain or lose weight when taking Caniquantel?

Weight changes (either gain or loss) are not listed as a documented adverse reaction in the official prescribing information for this medicine.


Q: Are there different forms of Caniquantel (e.g., tablet, liquid)?

The product is officially manufactured and authorized as a tablet intended for oral use. Official regulatory documentation does not typically describe other pharmaceutical forms, such as a liquid, under the same authorization.


Q: If I miss a dose of Caniquantel, what should I do?

Standard product information for the components of this medicine typically advises administering a missed dose when remembered, unless it is nearly time for the next scheduled dose. It is generally advised not to administer two doses at once.


Q: Does taking Caniquantel at a certain time of day matter?

The official instructions for correct administration do not specify a required time of day. It can be administered at any time, either directly or conveniently mixed with food.


Q: Can Caniquantel affect your mood or emotional state?

The safety profile lists lethargy (sluggishness or drowsiness) as an uncommon adverse reaction related to the nervous system. While lethargy is a documented effect, official regulatory documents do not explicitly list changes to emotional state or mood.


Q: Is there a generic version of Caniquantel available?

The active substances (Praziquantel and Fenbendazole) are used in multiple authorized veterinary products. The availability of a direct generic alternative for the Caniquantel brand varies by market and local regulatory approval status.


Q: Are there any specific lifestyle changes that enhance Caniquantel's effectiveness?

Official information notes that administering the medicine with food significantly increases the systemic absorption of the Fenbendazole component, which is one of the active ingredients.


Q: How is Caniquantel eliminated from the body?

Pharmacokinetic studies show that the two active components are eliminated through different routes. Praziquantel and its metabolites are mainly eliminated through the urine, while Fenbendazole and its metabolites are eliminated primarily via the faeces.

How should Caniquantel be stored and disposed of?

Storage Requirements

Official regulatory documentation defines specific environmental and container conditions necessary to maintain the quality and shelf-life of Caniquantel tablets.

  • Temperature: Store at temperatures below 30 C or within the 15 C – 25 C room temperature range.
  • Protection: The product must be stored in a dry place and be protected from light.
  • Container and Stability: The labeled shelf-life of 3 or 4 years is for the product as packaged for sale, requiring it to remain in its original container until use.
  • Child Safety: It is mandatory to keep out of the sight and reach of children.

Disposal Instructions

Unused, expired, or unwanted Caniquantel or waste materials derived from it must be disposed of according to local requirements [2.5]. Disposal should be conducted in compliance with official environmental waste management procedures, and the product should not be disposed of via household wastewater or unchecked trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Caniquantel found in:

A-Z Index: